Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene.

By Katrina M. Comerford, T. Wallace, Jörn Karhausen, N. Louis, Michael Montalto, S. Colgan. Cancer Research, 2002

852 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/6b1f4cb2bc9d80c5c3bb0b969dc149ab8305e6a7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. H. Eltzschig
2. C. Wigerup
3. G. Semenza
4. S. Påhlman
5. J. Markman
6. Ming Tan
7. Hanchen Li
8. D. Bexell

Citations in the corpus

• Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy (2012, background): “First, HIFs have been shown to regulate the expression of genes encoding ATP-binding cassette multidrug transporters, including MDR1 (ABCB1) and BCRP (ABCG2), which efflux chemotherapy drugs from cancer cells [77, 78].”
• Nanomedicine therapeutic approaches to overcome cancer drug resistance (2013, background): “This reduced blood flow may lower concentrations of chemotherapeutics in hypoxic cells [71].”
• Tumor microenvironment: The role of the tumor stroma in cancer (2007, background): “To facilitate restructuring, fibroblasts, macrophages, and ECs of the stroma express and secrete MMPs. Secretion of these molecules by the stromal cells is the result of a complex tumor-stroma crosstalk, involving multiple ligands and cellular signaling pathways [Stuelten et al., 2005].”
• Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. (2016, background): “of various chemotherapeutic drugs and contribute to hypoxia-induced drug resistance (Comerford et al., 2002).”
• Targeting cellular metabolism to improve cancer therapeutics (2013, background): “Active drug efflux is also fueled by glycolytic ATP production and HIF-1a-induced transporter overexpression resulting in a significant decrease in the cytoplasmic retention of many anticancer agents.(110,111) HIF-1a overexpression also induces cellular compensations that can bypass the mechanisms o”
• Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. (2002, background): “Of note, it was recently reported that the MDR1 gene product P-glycoprotein could also contribute a similar function during hypoxia (54), particularly since MDR has been associated with barrier abnormalities in intestinal disease (55).”
• Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. (2007, result): “Genes that were found to be upregulated included PGK-1, CxCR4, LoxL2, and phosphofructokinase (PFKFB3).”
• Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. (2004, unknown): “(P-GP) (8, 9), were prominently induced (Figure 1I).”
• Tumors as organs: complex tissues that interface with the entire organism (2010, unknown): “…produce resistance to chemotherapeutic drugs through gene expression, such as HIF-1a-mediated upregulation of antiapoptotic proteins (e.g., Bcl-xL and heat shock proteins) or the multidrug resistance gene product P-glycoprotein (MDR1; Baird et al., 2006; Chen et al., 2009; Comerford et al., 2002).”